Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2005
08/31/2005CN1216640C Live vaccine for human immunodeficiency virus
08/31/2005CN1216605C Combination therapy for treatment of tumors
08/30/2005US6936704 a nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro
08/30/2005US6936698 Genetically engineered immunoglobulin; for use in treatment of hematopoietic defects
08/30/2005US6936689 Peptide antagonists of zonulin and methods for use of the same
08/30/2005US6936468 Oligodeoxyribonucleotide having one or more NF- kappa B binding sites.
08/30/2005US6936465 Plasmid vector comprising a retroviral integrase gene and an integrase recognition region
08/30/2005US6936464 Immune responses to fusion proteins
08/30/2005US6936448 As additives for human nutritive compositions or immunotherapeutics for cancer
08/30/2005US6936440 Selecting ligand agonists and antagonists
08/30/2005US6936425 Attenuated salmonella SP12 mutants as antigen carriers
08/30/2005US6936424 Materials and methods for detection and treatment of breast cancer
08/30/2005US6936263 Th1 inducing natural adjuvant for heterologous antigens
08/30/2005US6936262 Animal feeds; pneumonia vaccine
08/30/2005US6936261 Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
08/30/2005US6936260 For tubercolosis, antigen is inactivated Mycobacterium tuberculosis bacteria, and the adjuvant is a mixture of a fatty acid and a monoglyceride; elicits lowest tumor necrosis factor alpha (TNF-alpha); dosage forms such as nose drops
08/30/2005US6936259 For therapy and prophylaxis of bacterial infections
08/30/2005US6936258 Staphylococcus antigen and vaccine
08/30/2005US6936257 Recombinant Venezuelan equine encephalitis virus vaccine
08/30/2005US6936256 For controlling Infectious Pancreatic Necrosis Virus (IPNV) in aquatic species
08/30/2005US6936255 adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21
08/30/2005US6936254 Method of inducing fetal hemoglobin synthesis
08/30/2005US6936253 Ganglioside-KLH conjugate vaccines plus QS-21
08/30/2005US6936252 Streptococcus pneumoniae proteins and nucleic acid molecules
08/30/2005US6936250 Polysaccharide encapsualted antigen
08/30/2005US6936248 Methods of inhibiting GPR-9-6 function
08/30/2005US6936247 Filariid anti-P22U antibodies
08/30/2005US6936246 Passive immunization of ASCR for prion disorders
08/30/2005CA2103887C Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
08/30/2005CA2063587C Stable vaccine compositions containing interleukins
08/30/2005CA1341488C Precursor antigens for human retorvirus (hiv-2) envelope glycoproteins, and immunologically related antigens
08/27/2005WO2005076696A2 Pneumolysin derivatives
08/27/2005CA2555803A1 Pneumolysin derivatives
08/25/2005WO2005078087A1 Antibody targeting osteoclast-associated protein
08/25/2005WO2005078075A2 Hybrid proteins of active-site serine beta-lactamase
08/25/2005WO2005078068A1 Live attenuated salmonella for use as vaccine
08/25/2005WO2005077981A2 Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
08/25/2005WO2005077979A1 Method for obtaining antibodies requiring the use of a set of electromagnetic fields
08/25/2005WO2005077972A1 Ornithobacterium rhinotracheale subunit vaccines
08/25/2005WO2005077462A2 Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
08/25/2005WO2005077417A1 Inhibition of factor b, the alternative complement pathway and methods related thereto
08/25/2005WO2005077415A1 Pharmaceutical composition for treatment of immunological disorders
08/25/2005WO2005077414A1 Highly concentrated liquid formulations of anti-egfr antibodies
08/25/2005WO2005077413A1 Ctgf as target for the therapy of diabetic nephropathy
08/25/2005WO2005077412A2 Compositions and methods of use of w-peptides
08/25/2005WO2005077411A2 Composition and method for the treatment of carcinoma
08/25/2005WO2005077410A1 Methods and compositions for dosing of allergens
08/25/2005WO2005077409A1 A vaccine formulated for administration to mucosa of the lungs
08/25/2005WO2005077408A2 Compositions of pamps and listeria monocytogenes and methods of use
08/25/2005WO2005077407A1 Targeted atherosclerosis treatment
08/25/2005WO2005077299A1 Isolated plasma and method for hyperimmunisation and plasma collection
08/25/2005WO2005077130A2 A method for the removal of aggregate proteins from recombinant samples using ion exchange chromatography
08/25/2005WO2005077093A2 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
08/25/2005WO2005077090A2 Improved methods of producing antibody conjugates
08/25/2005WO2005077048A2 Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
08/25/2005WO2005077018A2 Methods of treating skin disorders
08/25/2005WO2005077003A2 Pili from mycobacterium tuberculosis
08/25/2005WO2005076975A2 Complexed polypeptide and adjuvant for improved vaccines
08/25/2005WO2005076965A2 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
08/25/2005WO2005076843A2 Methods and compositions for treating tumors and metastatic disease
08/25/2005WO2005065707A3 Recombinant vaccine against japanese encephalitis virus [jev] infection and a method thereof
08/25/2005WO2005058967A8 Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
08/25/2005WO2005058349A3 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
08/25/2005WO2005055945A3 Mucoadhesive drug delivery devices and methods of making and using thereof
08/25/2005WO2005053739A3 Combination therapy
08/25/2005WO2005051991A3 Mucin antigen vaccine
08/25/2005WO2005044307A3 Methods of therapy for b cell-related cancers
08/25/2005WO2005037868A3 Methods of treating nfat-related disorders
08/25/2005WO2005037194A3 Collagen interactions with prostate cancer cells
08/25/2005WO2005033134A3 Secreted protein therapeutics and uses thereof
08/25/2005WO2005028510A3 Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity
08/25/2005WO2005027963A3 METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV
08/25/2005WO2004113500A3 B7s1: an immune modulator
08/25/2005WO2004078203A9 Infectious bronchitis virus with an altered spike gene
08/25/2005WO2004058292A8 Methods and compositions for suppressing fibrocyte differentiation
08/25/2005WO2004043988A8 Ptprk immunogenic peptide
08/25/2005US20050187180 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
08/25/2005US20050187179 treatment of tumors which have increased Notch expression; administration of either Notch antisense oligonucleotides or monoclonal antibodies directed to Notch along with cell differentiating agent
08/25/2005US20050187161 peptide sequences that selectively bind to fungal surface molecules; Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) provides for rapid and efficient separation of phage that bind to fungal surface molecules
08/25/2005US20050187159 Covalently bonding albumin to oligopeptide; biochemical conjugation; analyzing stability, therapy
08/25/2005US20050187152 Prevention and treatment of hypergastrinemia
08/25/2005US20050186664 Albumin fusion proteins
08/25/2005US20050186663 Cystine-knot fold protein
08/25/2005US20050186660 Using calcitonin precursor protein as diagnostic tool in detection of cancer and sepsis
08/25/2005US20050186628 Dorsalin-1 polypeptide and uses thereof
08/25/2005US20050186621 Using host cells to propagate preferential viral proteins for use in generating vaccines aganist microorganismal infection
08/25/2005US20050186620 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response
08/25/2005US20050186612 Dendritic cell receptor
08/25/2005US20050186575 Corona-virus-like particles comprising functionally deleted genomes
08/25/2005US20050186571 Diagnosis and prevention of cancer cell invasion
08/25/2005US20050186568 Enzymatic polypeptides for use as drug screening tools; pharmacological toxicity
08/25/2005US20050186563 Expression vector for use as transformation and gene expression tool in genetic engineering; minimum plasmid-based system for the generation of infectious RNA viruses, preferably influenza viruses, from cloned DNA
08/25/2005US20050186562 Method for early detection during the clinical phase of the infection, reliable, rapid, inexpensive, making it possible to adapt the medical care in time
08/25/2005US20050186560 Mammalian cell expressing viral replication protein for use as tool in identifying modulators for treatment of cell proliferative and autoimmune disorders; immunotherapy
08/25/2005US20050186287 Use of copper agonists such as divalent metal ions, oligopeptides, oligonucleotides, oligosaccharides, nucleotide analogs that bind to copper binding site of amyloid precursor protein and reduce or prevent release of amyloid A beta peptide; prevention or treatment of Alzheimer's disease
08/25/2005US20050186266 Chlamydia antigens and corresponding DNA fragments and uses thereof
08/25/2005US20050186228 Coccidial vaccine and methods of making and using same
08/25/2005US20050186227 For protection of fetuses from abortion; freeze drying
08/25/2005US20050186226 treating diseases such as HIV/AIDS disease, oncological ailments, tuberculosis, rheumatics, etc. by autohaemovaccinoimmunotherapy
08/25/2005US20050186224 Attenuated bovine respiratory syncytial virus
1 ... 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 ... 1823